9 September 2021 - Late treatment study
Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial
et al., Nature Medicine, doi:10.1038/s41591-021-01488-2 (Peer Reviewed)
RCT 940 hospitalized patients, 614 assigned to convalescent plasma, showing no significant differences. NCT04348656.
|
risk of death, 13.0% higher, RR 1.13, p = 0.33, treatment 156 of 625 (25.0%), control 69 of 313 (22.0%), day 90.
|
|
risk of death, 12.0% higher, RR 1.12, p = 0.40, treatment 141 of 614 (23.0%), control 63 of 307 (20.5%), day 30.
|
|
risk of death/intubation, 16.0% higher, RR 1.16, p = 0.18, treatment 199 of 614 (32.4%), control 86 of 307 (28.0%).
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. |
Bégin et al., 9/9/2021, Randomized Controlled Trial, multiple countries, multiple regions, peer-reviewed, 32 authors.
Please send us
corrections, updates, or comments. Vaccines and treatments are both
valuable and complementary. All practical, effective, and safe means
should be used. Elimination of COVID-19 is a race against viral evolution. No
treatment, vaccine, or intervention is 100% available and effective for all
current and future variants. Denying the efficacy of any method increases
mortality, morbidity, collateral damage, and the risk of endemic status. We do
not provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. WCH
and FLCCC provide
treatment protocols.